Moderna’s stock rose over 3% on Friday after the biotech company posted a wider-than-expected loss in the fourth quarter, but received positive news from its vaccine sales. The company’s COVID-19 vaccine sales exceeded expectations, while its RSV vaccine sales were modest. However, despite this, Moderna offered soft guidance for 2025, which helped to offset the revenue beat and boosted investor confidence.
Source: https://www.marketwatch.com/story/modernas-wider-than-expected-loss-and-soft-guidance-weigh-on-battered-stock-64076d2f